SCHEMBL25504246

SCHEMBL25504246

CCN1CCC(C)(NC(=O)c2cnccc2C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.43
SMYD3 Q9H7B4 1/20 0.43
SIRT3 Q9NTG7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
HASPIN Q8TF76 1/20 0.39
NAMPT P43490 3/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DRD2 P14416 2/20 0.37
FPR3 P25089 1/20 0.37
FPR2 P25090 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ACKR3 P25106 1/20 0.37
OPRM1 P35372 2/20 0.36
OPRD1 P41143 2/20 0.36
OPRK1 P41145 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068968 0.86 SIRT3 (0.44) RETSMYD3SIRT3TDP1NAMPT
SCHEMBL22857013 0.83 RET (0.44) RETSMYD3SIRT3TDP1NAMPT
SCHEMBL20147647 0.83 SMYD3 (0.45) RETSMYD3SIRT3TDP1NAMPT
SCHEMBL25504103 0.80 RET (0.43) RETMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL20147988 0.79 THRB (0.49) RETNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL25504250 0.78 P2RX7 (0.51) RETMAPTSMN1; SMN2DRD2KDM4E
SCHEMBL21651991 0.78 CCR3 (0.49) RETDRD2CCR3
SCHEMBL20205890 0.78 MAPT (0.47) RETMAPTDRD2CCR3P2RX7
SCHEMBL25503767 0.76 MCHR1 (0.47) RETMAPTNPC1RAB9AKDM4E
SCHEMBL21652023 0.76 CCR3 (0.49) RETMAPTDRD2KDM4EACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885SMYD3 1177/4885SIRT3 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.